 Seres Therapeutics Inc NASDAQ: MCRB has announced topline results from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis UC. The study did not meet its primary endpoint of improving clinical remission rates compared to placebo. 